Ranking Invest

Bristol-Myers Squibb Company

Segmento: Healthcare Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Indicadores Básicos

Valor de Mercado

$ 98.28 Bi

IVR

0.25

IVR2

0.11

Índices de Previsibilidade

Faturamento

0.03

Lucro

0.28

Margem

0.29

Índices de Tendência

Faturamento

1.18

Lucro

-0.51

Margem

-0.20

Índices de Endividamento

DIV/PAT

2.33

DIV/L4T

7.45

Dívida Líquida

$ 40.36 Bi

Patrimônio Líquido

$ 17.33 Bi

L4T

$ 5.42 Bi

MM4T

11.62%

Dívidas
Dividendos
Cotação: $48.34

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre